Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALAPRO-1 talazoparib in DDR-positive metastatic castration-resistant prostate cancer
2016-002036-32Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talazoparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Pfizer. Primary endpoint: Best objective response rate. Started Sep 2016; status: completed.
02
Drugs
talazoparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2016-002036-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002036-32.